Bli medlem
Bli medlem

Du är här


Wilson Therapeutics AB: Wilson Therapeutics announces that the ongoing Phase II study has been fully enrolled

Wilson Therapeutics AB (publ), announces that the company's ongoing
Phase II clinical trial evaluating the safety and efficacy of
Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease
patients has been fully enrolled.

WTX101-201 is a Phase II clinical trial evaluating the efficacy and
safety of Decuprate® monotherapy dosed once daily in newly-diagnosed
patients with Wilson Disease, aged 18 years and older, who previously
have been treated with a standard of care agent for up to two years,.
The study is being conducted at 11 sites in the U.S. and Europe, and
will follow patients on Decuprate® for 24 weeks. Patients completing
the 24 weeks can elect to stay on Decuprate® in an extension phase of
the study.

As of May 18, 28 patients have been enrolled in the study and six
patients have reached the end of the 24-week treatment period. All
six patients have elected into the extension phase. The patients
recruited had various degrees of hepatic impairment at the time of
enrollment and the majority of enrolled patients had neurological
symptoms at study start.

"We are excited that the phase II study is now fully enrolled and that
the trial is progressing according to plan," says Carl Bjartmar,
Chief Medical Officer of Wilson Therapeutics. "The preliminary data
are encouraging as they seem to support the promise that Decuprate®
could offer an efficacious and well tolerated treatment option with a
lowered risk of an initial neurological worsening in patients with
Wilson Disease."

Michael Schilsky (MD, FAASLD), Associate Professor at Yale Medical
Center and Director, Center of Excellence for Wilson Disease
continues: "We are very pleased with the progression of this study.
Although treatments for Wilson Disease have been available since the
1950's, there is a clear need for novel therapies that can address
the significant unmet medical needs. Currently we are seeking
treatment that yields a higher initial response rate and a more
benign side effect profile. The study is ongoing so the data are
still preliminary, but they are promising as they indicate that
Decuprate® may address these needs. With the possibility of once
daily dosing that could improve patient convenience and adherence, a
successful outcome for the trial should lead to significant
improvements for Wilson Disease patients."

"The full enrollment of the Phase II trial is a significant milestone
in the development program," says Jonas Hansson, Chief Executive
Officer of Wilson Therapeutics. "We now look forward to the six-month
data from all subjects. Shortly after we have received and analyzed
the Phase II data we intend to go back to the regulatory authorities
to discuss the Phase III program."

About Decuprate® (bis-choline tetrathiomolybdate; WTX101)
Decuprate® is a first-in class de-coppering agent with a novel and
unique mechanism of action. With its strong and selective binding to
copper, Decuprate® has the potential to expand the body's own liver
buffering capacity for copper, which is saturated in patients with
Wilson Disease. The active ingredient of Decuprate®,
tetrathiomolybdate, has been tested in several clinical studies in
Wilson Disease patients and the data from these studies, as well as
preliminary data from the Company's ongoing Phase II study, suggest
that Decuprate® can rapidly lower and control toxic free copper
levels and improve clinical symptoms in these patients. The data also
suggest that Decuprate® is well-tolerated with the potential for a
reduced risk of neurological worsening after initiation of therapy
compared to existing therapies. Decuprate® is expected to have a
once-daily dosing regimen which may potentially translate into to
improved compliance in Wilson Disease patients, leading to fewer
treatment failures and ultimately improved outcomes as a result.
Decuprate® has received orphan drug designation for the treatment of
Wilson disease in the US and EU.

About Wilson Disease
Wilson Disease is a rare genetic disease that causes serious copper
poisoning. The genetic defect causes excessive copper accumulation,
primarily in the liver and/or the central nervous system and the
disease results in life-threatening damage to the liver and brain if
left untreated. Wilson Disease affects approximately one in every
30,000 people worldwide, corresponding to a prevalence of
approximately 10,000 patients in the US and 15,000 patients in the
EU. The therapies currently being used in Wilson Disease were
introduced in the 50's and 60's and since then there have been no new
treatment options developed for patients with this disease.

About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in
Stockholm, Sweden, that develops novel therapies for patients with
rare diseases such as Wilson Disease. Wilson Therapeutics' lead
product, Decuprate®, is initially being developed as a novel
treatment for Wilson Disease and is currently being evaluated in a
Phase II clinical study in Wilson Disease patients. Wilson
Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm
with the stock ticker WTX.

Visit for more information.
For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Wilson Therapeutics AB (publ)
Org nr 556893-0357
Västra Trädgårdsgatan 15
SE-111 53 Stockholm
The information in the press release is such that Wilson Therapeutics
is required to disclose publicly in accordance with the Swedish
Securities and Clearing Operations Act and/or the Swedish Financial
Instruments Trading Act. The information was submitted for
publication on May 18, 2016 at 8:00 a.m.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.